Table 2.

The reward deficiency syndrome theorem.

Reference	Topic	Comment
[43]	Neurogenetic evidence for Genetic Addiction Risk Score (GARS)	Developed Genetic Addiction Risk Score(GARS) to identify risk for RDS
[44]	Developed DNA directed gene guided therapy with pro-dopamine regulation	Provided first evidence for nutrigenomic coupled precision personalized treatment for obesity
[45]	Enhanced resting-state functional connectivity in naive animal models with enkephalinase inhibition	The first study to show activation of mesolimbic dopaminergic activation across brain reward circuitry with Pro-dopamine regulation
[46]	Enkephalinase opioid substitution therapy during withdrawal from Bup/Nal	Pro-dopamine agonist therapy blocks opioid withdrawal and maintains opioid-free urines for 432 days
[47]	Enkephalinase inhibition attenuation of opioid detoxification	Pro-dopamine regulation as a frontline technology to induce detoxification reducing withdrawal symptoms in opioid dependence
[48]	Opioid/dopamine deficiency genotype theorem	Early theory proposing that genetic or epigenetic insult onto endogenous opioid peptides and dopamine will induce drug-seeking
[49]	Enkephalinase inhibition attenuation of alcohol binge in drinking in rodents	Significant reduction of binge drinking in an animal model of binging in genetically prone animals with Pro-dopamine regulation
[50]	Development of DNA directed precision addiction management	Proposed coupling of GARS and KB220 matched algorithmic polymorphic nutrigenomic anti-RDS
[42]	rsfMRI effects of KB220Z™ on neural pathways in the reward circuitry of abstinent genotyped heroin addicts	Enhanced functional connectivity and neuronal dopaminergic recruitment in abstinent heroin addicts